tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market
IKT
Inhibikase Therapeutics
RESEARCH TOOLSreports
Want to see IKT full AI Analyst Report?

Inhibikase Therapeutics (IKT) Stock News & Sentiment

383 Followers
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
Premium
Company Announcements
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
11d ago
IKT
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
Premium
Company Announcements
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
12d ago
IKT
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
Premium
Ratings
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
2M ago
IKT
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
Premium
Ratings
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
2M ago
IKT
Inhibikase Begins Pivotal Phase 3 Trial in PAH
Premium
Company Announcements
Inhibikase Begins Pivotal Phase 3 Trial in PAH
2M ago
8K
IKT
IKT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
IKT Upcoming Earnings Report: What to Expect?
2M ago
IKT
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
Premium
Ratings
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
3M ago
IKT
More IKT News >

IKT News on the Web

Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
Inhibikase Therapeutics (IKT) Gets a Buy from Cantor Fitzgerald
TipRanks News
Neutral
LifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)
TipRanks News
Bullish
Analysts Are Bullish on These Healthcare Stocks: Milestone Scientific (MLSS), Inhibikase Therapeutics (IKT)
TipRanks News
Neutral
Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)
TipRanks News
Bullish
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
TipRanks News
Bearish
Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and PepGen Inc. (PEPG)
TipRanks News
Bullish
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
IKT
Sector Average
Media Buzz
This Week2 articles
Weekly Average1.5 articles
News Sentiment
This Week100%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IKT’s Media Buzz Sentiment?
2 articles about IKT were published this week. In an average week, 1.5 articles are published.
    What is IKT’s weekly average amount of articles?
    In an average week, 1.5 articles about IKT are published.
      What is IKT’s News Sentiment?
      100% of articles about IKT were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        TLSATiziana Life Sciences
        Showing the stocks with the most bullish news sentiment over the past week